project id: TCGA-BLCA; case submitter id: TCGA-UY-A78N; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.94; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.69; rna integrity number: 8.2; age at index: 80; days to birth: -29132; days to death: 2641; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Dead; age at diagnosis: 29132; ajcc pathologic m: MX; ajcc pathologic n: N1; ajcc pathologic stage: Stage IV; ajcc pathologic t: T2; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: Not Reported; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 1.36986301369863; pack years smoked: 25.0; is ffpe: false; composition: Not Reported; days to sample procurement: 0; initial weight: 340.0; portion submitter id: TCGA-UY-A78N-01A-12; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 2.0; percent necrosis: 3.0; percent neutrophil infiltration: 5.0; percent normal cells: 0.0; percent stromal cells: 27.0; percent tumor cells: 70.0; percent tumor nuclei: 70.0;